Advertisement
U.S. markets open in 3 hours 22 minutes

Catalent, Inc. (CTLT)

NYSE - NYSE Delayed Price. Currency in USD
55.96-0.26 (-0.46%)
At close: 04:00PM EDT
55.75 -0.21 (-0.38%)
Pre-Market: 04:09AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close56.22
Open56.54
Bid0.00 x 800
Ask0.00 x 1300
Day's Range55.90 - 56.54
52 Week Range31.45 - 68.81
Volume1,730,133
Avg. Volume2,796,421
Market Cap10.114B
Beta (5Y Monthly)1.20
PE Ratio (TTM)N/A
EPS (TTM)-7.18
Earnings DateMay 17, 2024 - May 21, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est57.32
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CTLT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Catalent, Inc.
    Analyst Report: Catalent, Inc.Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
    Rating
    Fair Value
    Economic Moat
    last monthMorningstar
View more
  • InvestorPlace

    The Top 3 Pharma Stocks to Buy in March 2024

    Investors’ eyes are closely following the massive rally in pharmaceutical stocks amid the red-hot anti-obesity market. In 2024, the projected revenue for the pharma market is estimated to reach $1.15 trillion. And, oncology drugs are expected to be the largest segment at $214.1 billion, according to Statista. One sub-sector has been of particular interest in recent months – the anti-obesity drugs market. The global market for anti-obesity medications (AOMs) reached $6 billion annually earlier th

  • Reuters

    HIGHLIGHTS-Novo Nordisk hopes to launch experimental obesity drug this decade

    Novo Nordisk's head of development on Friday told Reuters he was very comfortable the drugmaker would be able to launch the pill version of its experimental weight loss drug amycretin this decade. Research head Lange said the drugmaker could launch the pill version of its experimental weight loss drug amycretin this decade. It expects both new experimental obesity drugs cagrisema and amycretin to lead to greater weight loss than its hugely popular Wegovy.

  • Business Wire

    Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment

    SOMERSET, N.J., March 07, 2024--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, has today published its fiscal 2023 Corporate Responsibility Report, highlighting positive progress across every pillar of Catalent’s corporate responsibility strategy – People, Environment, and Community. The report also outlines the company’s future commitments as it progresses its mission to help people lead better and healthier lives.